ESC Congress 2026 Abstract
Inclisiran helped more high-risk people reach cholesterol goals
At 360 days, 89.5% reached cholesterol goals with inclisiran plus optimized therapy, versus 62.2% with optimized therapy plus placebo.At 360 days, 89.5% reached cholesterol goals with inclisiran plus optimized therapy, versus 62.2% with optimized therapy plus placebo.
Randomized trial · 1,770 peopleInclisiran
Who was studied1,770 high-risk people with high cholesterol taking statins, 360 days
What changedAt 360 days, cholesterol goals were reached by 89.5% with inclisiran plus optimized therapy versus 62.2% with placebo plus optimized therapy
The catchCholesterol targets, rather than heart attacks or lifespan, were assessed